Drug of Abuse Testing Market
Market Insights on Drug of Abuse Testing covering sales outlook, demand forecast & up-to-date key trends
Drug of Abuse Testing Market by Product Type (Psychostimulants, Narcotic, Cannabinoids, Sedatives, Others), Technique (Immunoassay, Chromatography, Rapid Testing), End User (Hospitals, Diagnostics Laboratories, Forensic Laboratories & Others) & Region - Forecast to 2021 - 2031
Drug of Abuse Testing Market Snapshot
[185 Pages Report] Newly released data by Future Market Insights (FMI) shows that the global drug of abuse testing market is projected to reach a valuation of US$ 1.5 Bn in 2021, with sales growing at above 5% CAGR through 2031.
Growing prevalence of opioid dependence among the geriatric population will fuel the demand for drug of abuse tsesting services. Besides this, sales of drug of abuse testing kits is expected to rise as a result of high demand for rapid and accurate drug testing equipment in forensic laboratories, hospitals, and senior citizen care centers.
|
Attribute |
Details |
|
Estimated Drug of Abuse Testing Market Size in 2021 |
US$ 1.5 Bn |
|
Drug of Abuse Testing Market Value CAGR (2021-2031) |
~5% |
Let us know your requirement to get
100% FREE customization
Drug of Abuse Testing Market Historic Sales Compared to 2021-2031 Forecast Outlook
Demand for drug of use testing equipment grew at a 6.02% CAGR between 2016 and 2020. Sales prospects were however dampened due to the outbreak of the novel COVID-19 pandemic. Disruptions in supply chains and inadequate availability of raw material hampered production and sales of drug of abuse testing equipment and tools.
However, with expedited vaccine drives and resumption of transport, recovery of the global drug of abuse testing market is on cards. FMI has projected sales of drug of abuse testing systems to increase by 6.40% year-over-year between 2020 and 2021. Rising awareness regarding high consumption of illicit drugs and overdose of prescribed medications will continue propelling demand for drug of abuse testing systems.
Apart from this, increasing preference for on-the-spot and disposable testing methods for rapid detection of drug abuse is expected to provide tailwinds to sales of drug of abuse testing tools.
To gain a competitive edge, leading players operating in the global drug of abuse testing market are providing training on the identification and handling of illicit drugs to law enforcement authorities through online services. Such initiatives are expected to create lucrative opportunities for drug of abuse testing players over the forecast period.
How is Advent of Drug Warning Systems Affecting Drug of Abuse Testing Industry?
Substance use disorders (SUDs) have emerged as a burden on society. In many parts of the world, annual surveys of drug and substance use in households, schools, and workplaces serve as one of the primary sources of information that indicate illicit drug use.
Increasing rate of prescription drug abuse are underpinning the importance of adequate testing and abuse detection. Research also has shown substantial comorbidity of SUDs with psychiatric disorders and physical health issues.
However, drug abuse mapping has its own challenges, which hinder prospects of research in substance abuse epidemiology to devise modern solutions for drug abuse epidemics. Further, it is imperative to pinpoint factors that link with individual vulnerabilities of SUDs such as genetics, social and environmental risk factors.
As deaths associated with fentanyl and other psychostimulants continue to rise and new psychoactive continue to emerge, methods of drug administration are also evolving. There has been a substantial rise in vaping of cannabis among teenagers and adolescents. Further, the COVID-19 outbreak has triggered drug overdoses and changes in drug use behaviors among homebound individuals.
To tackle these problems, the National Drug Early Warning System (NDEWS) is launched in the U.S. The new system incorporates real-time surveillance to detect early signs of potential drug abuse. It includes 18 sentinel sites that utilize modern surveillance methods and gather data in a rapid, secure, and timely manner.
Data collection in real-time will provide a comprehensive characterization of drug use and the availability of on-ground epidemiologic investigations in high-priority areas of concern. Such developments and implementation of novel drug of abuse testing guidelines are expected to propel sales of drug of abuse testing over the assessment period.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow is Increasing Incidence of Drug Abuse among the Elderly Spurring Demand for Drug of Abuse Testing?
Chronic pain is more common and complicated in the geriatric population. According to the National Institute of Health (NIH), up to 80% of patients with cancer and 77% with heart disease have reported persistent pain. Patients are often prescribed opioid medications for pain management. However, regular opioid usage results in addiction, which also compels patients to resort to cheaper drugs.
Besides this, rising adoption of recreational marijuana for chronic pain management is also fueling addiction problems. Ongoing research and medical trials indicate that medical marijuana can improve sleep hygiene, malnutrition, depression, and other side effects of cancer treatment.
Regular usage of marijuana for medical or recreational purposes has also been linked to depression, impaired memory, adverse cardiovascular functions, altered judgment, and motor skills in the geriatric population. Cannabinoids can also interact with other prescription drugs and complicate pre-existing health issues in older adults.
As incidence of opioid dependence continues to rise, healthcare professionals and other medical institutes are running regular tests and screening of the elderly to diagnose signs of drug abuse at an early stage. This is expected to spur demand for drug of abuse testing tools and equipment in hospitals and diagnostics
Country-wise Insights
What will drive the U.S. Drug of Abuse Testing Market?
Rising prevalence of opioid dependence in the U.S. is expected to continue boosting demand for drug of abuse testing tools and equipment. Substance abuse rates during the COVID-19 pandemic have grown substantially in the country, with more individuals getting dependent on cannabinoids for stress and anxiety relief.
As per the National Centre for Drug Abuse Statistics, 53 million individuals over the age of 12 have used illegal drugs or have misused prescription drugs in 2020. Commonly abused prescribed stimulants include Adderall, Modafinil, Ritalin, and Concerta. Non-sanctioned use of these drugs leads to drug abuse.
In response to the growing drug dependence among individuals in the U.S., manufacturers are launching effective and accurate drug of abuse testing kits. Along with novel product launches, key manufacturers are also collaborating with research institutes and local authorities to spread awareness regarding drug abuse. This is expected to propel sales of drug of abuse testing in the U.S. over the forecast period.
Will the U.K. Drug of Abuse Testing Market Exhibit Consistent Growth?
The Centre for Social Justice determined that snowballing drug addiction in the U.K. has made it the “addiction capital of Europe”. Increasing usage of legal substances, mainly alcohol, and the usage of Class A drugs comprising heroin, meth, cocaine, and other hallucinogens is compelling authorities to launch drug testing protocols.
Causalities due to substance abuse in the U.K. is affecting users, as well as communities they belong to, and the society as a whole. Due to increasing costs of lab-based screening tests, hospitals and drug management authorities are adopting on-the-spot testing kits. Manufacturers are developing easy-to-use and disposable drug of abuse testing systems to cater to high demand from hospitals and forensic labs.
The aforementioned factors are anticipated to offer lucrative opportunities for drug of abuse testing market players operating in Europe, placing the U.K. as an attractive pocket for sales in the forthcoming years.
Why is China Drug of Abuse Testing Market Considered Lucrative?
Consistent usage of illicit drugs can lead to adverse mental and physical health disorders including cardiovascular diseases, fatal overdose, intentional or unintentional injuries, and even crime.
These issues later progress into clinical and social severity, difficulty in management of daily activities, morbidity, and non-adherence to treatment. This, coupled with the growing prevalence of alcohol dependence in China is compelling authorities to increase testing of drug abuse among citizens.
Sales of drug of abuse testing systems in China are expected to grow at a steady pace. The presence of key manufacturers, along with rapid expansion of the healthcare sector and easy availability of raw material are some factors expected to augment growth of the market through 2031.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Drug of Abuse Testing for Cannabinoids to Gain Momentum
As per National Centre for Drug Abuse Statistics, approximately 16.9% of American adults currently use marijuana. Marijuana is widely accepted as a recreational drug and is considered "less risky" than other substances such as alcohol, tobacco, and painkillers.
Growing popularity of cannabinoids can be attributed to their acceptance in modern society. As it is considered "less harmful", there has been less incidence of marijuana overdose. However, in some countries, consumption of marijuana is illegal even for recreational purposes. Marijuana addiction is rare, although overuse can still result in dementia, cardiovascular issues, and breathing disorders.
Owing to these factors, FMI has projected sales of drug for abuse testing for cannabinoids to continue gaining momentum through 2031.
Immunoassays to Remain Highly Sought-After Drug of Abuse Testing Technique
Demand for immunoassays is expected to rise at a steady pace over the forecast period owing to rising preference towards on-the-spot testing and higher adoption of disposable blood testing devices.
This technique is commonly used for drug testing in urine. Immunoassays are generally used for initial screening. Common formats of immunoassays used for drugs of abuse comprise EMIT (enzyme multiplied immunoassay technique), CEDIA (cloned enzyme donor immunoassays technique), and KIMS (kinetic interaction of microparticle in solution).
Sales of Drug of Abuse Testing in Forensic Laboratories to Continue Rising
Forensic drug chemistry is applied to identify illegal substances in the criminal justice system. Chemists use characteristics such as interaction of atoms and molecules, chemical signature, and unique to only those substances.
Forensic chemistry covers aspects including drugs, explosives, and poisons. As per FMI, forensic laboratories are projected to remain the prominent end-user of drug of abuse testing. Growing demand for accurate and proper testing of individuals consuming illicit drugs and retailing illegal substances is expected to propel sales of drug of abuse testing in forensic laboratories over the assessment period.
Competitive Landscape
Top 5 players operating in the global drug of abuse testing market comprise Quest Diagnostics, Roche Holding AG, Siemens AG (Siemens Healthineers), and Thermo Fisher Scientific, Inc. are the top players accounting for maximum sales in the market.
Leading players operating in the global drug of abuse testing market are focusing on research and development to launch novel testing tools that are more effective and accurate. Apart from this, players are investing in mergers, acquisitions, collaborations, and partnerships to expand their global footprint.
For instance, Abbott Laboratories partnered with Intoximeters in August 2019, allowing the latter to market Abbott's SoToxaTM Mobile Test System. This is a handheld solution for oral fluid roadside testing. It has been designed to allow rapid detection of recent drug use.
Scope of Report
|
Attribute |
Details |
|
Forecast Period |
2021-2031 |
|
Historical Data Available for |
2016-2020 |
|
Market Analysis |
USD Million for Value |
|
Key Regions Covered |
North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa |
|
Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa |
|
Key Segments Covered |
Drug, Technique, End User, and Regions |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
Drug of Abuse Testing Market by Category
By Drug Type:
- Psychostimulants
- Narcotic
- Cannabinoids
- Sedatives
- Others
By Technique:
- Immunoassay
- Chromatography
- Rapid Testing
By End User:
- Hospitals
- Diagnostics Laboratories
- Forensic Laboratories
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
Frequently Asked Questions
The global drug of abuse testing market is expected to reach as valuation of US$ 1559.5 Mn in 2021.
Demand for drug of abuse testing systems grew at a 6.02% CAGR between 2026 and 2020.
Rising preference for on-spot and disposable testing tools, along with increasing dependence on prescription drugs among the elderly for pain managements are some trends that are boosting sales of drug of abuse testing systems.
Quest Diagnostics, Roche Holding AG, Thermo Fisher Scientific, Inc., Siemens AG (Siemens Healthineers), Abbott Laboratories (Alere, Inc.), Shimadzu Corporation, Express Diagnostics International Inc., Drägerwerk AG & Co. KGaA, and Laboratory Corporation of America Holdings are among key players operating in the drug of abuse testing market.
Sales of drug of abuse testing in North America are expected to grow at a 4.56% CAGR over the assessment period.
Leading players operating in the global drug of abuse testing market are anticipated to hold 50-55% of the total market share over the assessment period.
The dug of abuse testing market is expected to expand at a 5.19% CAGR over the forecast period.
Japan is expected to hold 7%, while South Korea is anticipated to account for less than 1% of the total drug of abuse testing market share.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Market Background
3.1. Macro-Economic Factors
3.1.1. Growing Impact of Drug and Alcohol Abuse on Public Health
3.1.2. Rise in Law Enforcement Spending for Illicit Drug Interdiction
3.2. Forecast Factors - Relevance & Impact
3.2.1. Rise in Number of Clinical Laboratories offering Drugs of Abuse Testing Services
3.2.2. Awareness Initiatives from the Manufacturers
3.2.3. Rising R&D investments
3.2.4. Drug Abuse Testing Regulation
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints
3.3.3. Opportunity Analysis
4. Global Market Demand (Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021-2031
4.1. Historical Market Value (US$ Mn) Analysis, 2016-2020
4.2. Current and Future Market Value (US$ Mn) Projections, 2021-2031
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2016-2020 and Forecast 2021-2031, by Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2016–2020
5.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2021-2031
5.3.1. Psychostimulants
5.3.2. Narcotics
5.3.3. Cannabinoids
5.3.4. Sedatives
5.3.5. Others
5.4. Market Attractiveness Analysis By Drug Type
6. Global Market Analysis 2016-2020 and Forecast 2021-2031, by Technique
6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Mn) Analysis By Technique, 2016–2020
6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Technique, 2021-2031
6.3.1. Immunoassay
6.3.2. Chromatography
6.3.3. Rapid Testing
6.4. Market Attractiveness Analysis By Technique
7. Global Market Analysis 2016-2020 and Forecast 2021-2031, by End User
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By End User, 2016–2020
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2021-2031
7.3.1. Hospitals
7.3.2. Diagnostics Laboratories
7.3.3. Forensic Laboratories
7.3.4. Others
7.4. Market Attractiveness Analysis By End User
8. Global Market Analysis 2016-2020 and Forecast 2021-2031, by Region
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Region, 2016–2020
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2021-2031
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. APEJ
8.3.6. Japan
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2016-2020 and Forecast 2021-2031
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
9.3.1. By Country
9.3.1.1. U.S.
9.3.1.2. Canada
9.3.2. By Drug Type
9.3.3. By Technique
9.3.4. By End User
9.4. Market Attractiveness Analysis
9.4.1. By Country
9.4.2. By Drug Type
9.4.3. By Technique
9.4.4. By End User
9.5. Key Market Participants - Intensity Mapping
9.6. Drivers and Restraints - Impact Analysis
10. Latin America Market Analysis 2016-2020 and Forecast 2021-2031
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
10.3.1. By Country
10.3.1.1. Brazil
10.3.1.2. Mexico
10.3.1.3. Rest of Latin America
10.3.2. By Drug Type
10.3.3. By Technique
10.3.4. By End User
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Drug Type
10.4.3. By Technique
10.4.4. By End User
10.5. Key Market Participants - Intensity Mapping
10.6. Drivers and Restraints - Impact Analysis
11. Western Europe Market Analysis 2016-2020 and Forecast 2021-2031
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
11.3.1. By Country
11.3.1.1. Germany
11.3.1.2. UK
11.3.1.3. France
11.3.1.4. Spain
11.3.1.5. Italy
11.3.1.6. Nordic Countries
11.3.1.7. Rest of WE
11.3.2. By Drug Type
11.3.3. By Technique
11.3.4. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug Type
11.4.3. By Technique
11.4.4. By End User
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Eastern Europe Market Analysis 2016-2020 and Forecast 2021-2031
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
12.3.1. By Country
12.3.1.1. Russia
12.3.1.2. Poland
12.3.1.3. Rest of EE
12.3.2. By Drug Type
12.3.3. By Technique
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Type
12.4.3. By Technique
12.4.4. By End User
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. APEJ Market Analysis 2016-2020 and Forecast 2021-2031
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
13.3.1. By Country
13.3.1.1. China
13.3.1.2. India
13.3.1.3. Australia & NZ
13.3.1.4. ASEAN
13.3.1.5. Rest of APEJ
13.3.2. By Drug Type
13.3.3. By Technique
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Type
13.4.3. By Technique
13.4.4. By End User
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. Japan Market Analysis 2016-2020 and Forecast 2021-2031
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
14.3.1. By Country
14.3.1.1. Japan
14.3.2. By Drug Type
14.3.3. By Technique
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Type
14.4.3. By Technique
14.4.4. By End User
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2021-2031
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016–2020
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2021-2031
15.3.1. By Country
15.3.1.1. GCC Countries
15.3.1.2. South Africa
15.3.1.3. Rest of MEA
15.3.2. By Drug Type
15.3.3. By Technique
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Type
15.4.3. By Technique
15.4.4. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Competition Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Competition Deep Dive (Tentative List)
16.3.1. Quest Diagnostics
16.3.1.1. Overview
16.3.1.2. Service Portfolio
16.3.1.3. Profitability by Market Segments (Service/Channel/Region)
16.3.1.4. Sales Footprint
16.3.1.5. Strategy Overview
16.3.1.5.1. Marketing Strategy
16.3.1.5.2. Service Strategy
16.3.1.5.3. Channel Strategy
16.3.2. F. Hoffmann-La Roche Ltd
16.3.2.1. Overview
16.3.2.2. Service Portfolio
16.3.2.3. Profitability by Market Segments (Service/Channel/Region)
16.3.2.4. Sales Footprint
16.3.2.5. Strategy Overview
16.3.2.5.1. Marketing Strategy
16.3.2.5.2. Service Strategy
16.3.2.5.3. Channel Strategy
16.3.3. Siemens AG (Siemens Healthineers)
16.3.3.1. Overview
16.3.3.2. Service Portfolio
16.3.3.3. Profitability by Market Segments (Service/Channel/Region)
16.3.3.4. Sales Footprint
16.3.3.5. Strategy Overview
16.3.3.5.1. Marketing Strategy
16.3.3.5.2. Service Strategy
16.3.3.5.3. Channel Strategy
16.3.4. Thermo Fisher Scientific, Inc.
16.3.4.1. Overview
16.3.4.2. Service Portfolio
16.3.4.3. Profitability by Market Segments (Service/Channel/Region)
16.3.4.4. Sales Footprint
16.3.4.5. Strategy Overview
16.3.4.5.1. Marketing Strategy
16.3.4.5.2. Service Strategy
16.3.4.5.3. Channel Strategy
16.3.5. Abbott Laboratories (Alere, Inc.)
16.3.5.1. Overview
16.3.5.2. Service Portfolio
16.3.5.3. Profitability by Market Segments (Service/Channel/Region)
16.3.5.4. Sales Footprint
16.3.5.5. Strategy Overview
16.3.5.5.1. Marketing Strategy
16.3.5.5.2. Service Strategy
16.3.5.5.3. Channel Strategy
16.3.6. Shimadzu Corporation
16.3.6.1. Overview
16.3.6.2. Service Portfolio
16.3.6.3. Profitability by Market Segments (Service/Channel/Region)
16.3.6.4. Sales Footprint
16.3.6.5. Strategy Overview
16.3.6.5.1. Marketing Strategy
16.3.6.5.2. Service Strategy
16.3.6.5.3. Channel Strategy
16.3.7. Laboratory Corporation of America Holdings
16.3.7.1. Overview
16.3.7.2. Service Portfolio
16.3.7.3. Profitability by Market Segments (Service/Channel/Region)
16.3.7.4. Sales Footprint
16.3.7.5. Strategy Overview
16.3.7.5.1. Marketing Strategy
16.3.7.5.2. Service Strategy
16.3.7.5.3. Channel Strategy
16.3.8. Drägerwerk AG & Co. KGaA
16.3.8.1. Overview
16.3.8.2. Service Portfolio
16.3.8.3. Profitability by Market Segments (Service/Channel/Region)
16.3.8.4. Sales Footprint
16.3.8.5. Strategy Overview
16.3.8.5.1. Marketing Strategy
16.3.8.5.2. Service Strategy
16.3.8.5.3. Channel Strategy
16.3.9. Express Diagnostics International Inc.
16.3.9.1. Overview
16.3.9.2. Service Portfolio
16.3.9.3. Profitability by Market Segments (Service/Channel/Region)
16.3.9.4. Sales Footprint
16.3.9.5. Strategy Overview
16.3.9.5.1. Marketing Strategy
16.3.9.5.2. Service Strategy
16.3.9.5.3. Channel Strategy
17. Assumptions and Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Growth Comparison
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2021–2031, By Region
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2021–2031, By Drug Type
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2021–2031, By Technique
Table 05: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2021–2031, By End User
Table 06: North America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 07: North America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 08: North America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 09: North America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Table 10: Latin America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 11: Latin America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 12: Latin America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 13: Latin America Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Table 14: Western Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 15: Western Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 16: Western Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 17: Western Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Table 18: Eastern Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 19: Eastern Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 20: Eastern Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 21: Eastern Europe Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Table 22: APEJ Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 23: APEJ Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 24: APEJ Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 25: APEJ Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Table 26: Japan Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 27: Japan Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 28: Japan Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 29: Japan Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Table 30: MEA Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Country
Table 31: MEA Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Drug Type
Table 32: MEA Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By Technique
Table 33: MEA Market Value (US$ Mn) Analysis 2016-2020 and Forecast 2021–2031, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Mn), 2021-2031
Figure 02: Global Market Value Share By Drug Type 2021 (E)
Figure 03: Global Market Value Share By Technique 2021 (E)
Figure 04: Global Market Value Share By End User 2021 (E)
Figure 05: Global Market Value Share By Region 2021 (E)
Figure 06: Global Market Value Analysis (US$ Mn), 2016-2020
Figure 07: Global Market Value Forecast (US$ Mn), 2021-2031
Figure 08: Global Market Absolute $ Opportunity, 2021 - 2031
Figure 09: Comparison January 2018 and October 2021, Y-o-Y Forecast
Figure 10: Global Market Share Analysis (%), By Region, 2021 & 2031
Figure 11: Global Market Y-o-Y Analysis (%), By Region, 2021-2031
Figure 12: Global Market Attractiveness Analysis by Region, 2021-2031
Figure 13: Global Market Share Analysis (%), By Drug Type, 2021 & 2031
Figure 14: Global Market Y-o-Y Analysis (%), By Drug Type, 2021-2031
Figure 15: Global Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 16: Global Market Share Analysis (%), By Technique, 2021 & 2031
Figure 17: Global Market Y-o-Y Analysis (%), By Technique, 2021-2031
Figure 18: Global Market Attractiveness Analysis by Technique, 2021-2031
Figure 19: Global Market Share Analysis (%), By End User, 2021 & 2031
Figure 20: Global Market Y-o-Y Analysis (%), By End User, 2021-2031
Figure 21: Global Market Attractiveness Analysis by End User, 2021-2031
Figure 22: North America Market Value Share, By Drug Type (2021 E)
Figure 23: North America Market Value Share, By Technique (2021 E)
Figure 24: North America Market Value Share, By End User (2021 E)
Figure 25: North America Market Value Share, By Country (2021 E)
Figure 26: North America Market Value Analysis (US$ Mn), 2016-2020
Figure 27: North America Market Value Forecast (US$ Mn), 2021-2031
Figure 28: North America Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 29: North America Market Attractiveness Analysis by Technique, 2021-2031
Figure 30: North America Market Attractiveness Analysis by End User, 2021-2031
Figure 31: North America Market Attractiveness Analysis by Country, 2021-2031
Figure 32: Latin America Market Value Share, By Drug Type (2021 E)
Figure 33: Latin America Market Value Share, By Technique (2021 E)
Figure 34: Latin America Market Value Share, By End User (2021 E)
Figure 35: Latin America Market Value Share, By Country (2021 E)
Figure 36: Latin America Market Value Analysis (US$ Mn), 2016-2020
Figure 37: Latin America Market Value Forecast (US$ Mn), 2021-2031
Figure 38: Latin America Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 39: Latin America Market Attractiveness Analysis by Technique, 2021-2031
Figure 40: Latin America Market Attractiveness Analysis by End User, 2021-2031
Figure 41: Latin America Market Attractiveness Analysis by Country, 2021-2031
Figure 42: Western Europe Market Value Share, By Drug Type (2021 E)
Figure 43: Western Europe Market Value Share, By Technique (2021 E)
Figure 44: Western Europe Market Value Share, By End User (2021 E)
Figure 45: Western Europe Market Value Share, By Country (2021 E)
Figure 46: Western Europe Market Value Analysis (US$ Mn), 2016-2020
Figure 47: Western Europe Market Value Forecast (US$ Mn), 2021-2031
Figure 48: Western Europe Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 49: Western Europe Market Attractiveness Analysis by Technique, 2021-2031
Figure 50: Western Europe Market Attractiveness Analysis by End User, 2021-2031
Figure 51: Western Europe Market Attractiveness Analysis by Country, 2021-2031
Figure 52: Eastern Europe Market Value Share, By Drug Type (2021 E)
Figure 53: Eastern Europe Market Value Share, By Technique (2021 E)
Figure 54: Eastern Europe Market Value Share, By End User (2021 E)
Figure 55: Eastern Europe Market Value Share, By Country (2021 E)
Figure 56: Eastern Europe Market Value Analysis (US$ Mn), 2016-2020
Figure 57: Eastern Europe Market Value Forecast (US$ Mn), 2021-2031
Figure 58: Eastern Europe Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 59: Eastern Europe Market Attractiveness Analysis by Technique, 2021-2031
Figure 60: Eastern Europe Market Attractiveness Analysis by End User, 2021-2031
Figure 61: Eastern Europe Market Attractiveness Analysis by Country, 2021-2031
Figure 62: APEJ Market Value Share, By Drug Type (2021 E)
Figure 63: APEJ Market Value Share, By Technique (2021 E)
Figure 64: APEJ Market Value Share, By End User (2021 E)
Figure 65: APEJ Market Value Share, By Country (2021 E)
Figure 66: APEJ Market Value Analysis (US$ Mn), 2016-2020
Figure 67: APEJ Market Value Forecast (US$ Mn), 2021-2031
Figure 68: APEJ Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 69: APEJ Market Attractiveness Analysis by Technique, 2021-2031
Figure 70: APEJ Market Attractiveness Analysis by End User, 2021-2031
Figure 71: APEJ Market Attractiveness Analysis by Country, 2021-2031
Figure 72: Japan Market Value Share, By Drug Type (2021 E)
Figure 73: Japan Market Value Share, By Technique (2021 E)
Figure 74: Japan Market Value Share, By End User (2021 E)
Figure 75: Japan Market Value Share, By Country (2021 E)
Figure 76: Japan Market Value Analysis (US$ Mn), 2016-2020
Figure 77: Japan Market Value Forecast (US$ Mn), 2021-2031
Figure 78: Japan Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 79: Japan Market Attractiveness Analysis by Technique, 2021-2031
Figure 80: Japan Market Attractiveness Analysis by End User, 2021-2031
Figure 81: Japan Market Attractiveness Analysis by Country, 2021-2031
Figure 82: MEA Market Value Share, By Drug Type (2021 E)
Figure 83: MEA Market Value Share, By Technique (2021 E)
Figure 84: MEA Market Value Share, By End User (2021 E)
Figure 85: MEA Market Value Share, By Country (2021 E)
Figure 86: MEA Market Value Analysis (US$ Mn), 2016-2020
Figure 87: MEA Market Value Forecast (US$ Mn), 2021-2031
Figure 88: MEA Market Attractiveness Analysis by Drug Type, 2021-2031
Figure 89: MEA Market Attractiveness Analysis by Technique, 2021-2031
Figure 90: MEA Market Attractiveness Analysis by End User, 2021-2031
Figure 91: MEA Market Attractiveness Analysis by Country, 2021-2031
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
